Despite recent advances in the treatment of acute myeloid leukemia (AML), relapses remain
high, and long-term survival is poor, emphasizing the need for better treatment options …

There has been long-standing interest in using monoclonal antibodies to improve outcomes
of people with acute myeloid leukemia (AML). While several candidate therapeutics have …

Introduction Acute myeloid leukemia (AML) is the most common and deadly type of leukemia
affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed …

Abstract Purpose of Review The advent of several targeted agents has revolutionized the
treatment of acute myeloid leukemia (AML) in recent times; however, majority of patients are …

Among the few drugs that have shown a benefit for patients with acute myeloid leukemia
(AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug …

Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

Antigen-specific immunotherapies have long been pursued as a means to improve the
outcomes of patients with acute myeloid leukemia (AML). Success thus far has been limited …

Antigen-specific immunotherapies have emerged as important components of curative
treatment algorithms for many cancers. In acute myeloid leukemia (AML), success has been …

Monoclonal antibodies have become an important treatment modality in cancer therapy.
Genetically engineered chimaeric and humanised antibodies have demonstrated activity …

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML).
Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for …